Isicom (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing levodopa from being metabolized before it reaches the brain, thereby increasing its central availability and reducing peripheral side effects.

The appropriate dose of Isicom is individualized by the prescribing clinician based on the patient's disease severity, response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing adverse effects.

The safety of levodopa/carbidopa in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Isicom product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Isicom combines levodopa with carbidopa, offering a direct dopamine replacement strategy. Compared with dopamine agonists, it generally provides more robust symptom relief but may have a higher risk of motor complications over time. The combination reduces peripheral side effects relative to levodopa alone, making it a common first‑line option.

Isicom should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Isicom is taken orally, usually with a small amount of food to reduce gastrointestinal irritation. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare provider.

Serious risks include dyskinesia (involuntary movements), severe orthostatic hypotension, psychiatric disturbances such as hallucinations or confusion, and rare cardiac arrhythmias. Patients should be monitored regularly for these events, and any concerning symptoms should be reported to a clinician promptly.

Isicom is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, as it may exacerbate the condition.